In current clinical diagnosis strategy, the presence of amyloid β (regardless of the presence of phosphorylated tau or neurodegeneration) which is cleaved from the larger precursor amyloid precursor protein (APP), remains one of the key markers for the diagnosis of AD pathological change [13]. This evidence concerns the gene MAPT and Alzheimer disease.